,
Estelle Nadine Sanou,
Isidore Tiandiogo Traore,
Jean Kabore,
Clarisse Balima,
Djibril Barry,
Hermann Yoda,
Hermann Nikiema,
Smaila Ouedraogo,
Nicolas Meda
Background: Non-compliance with treatment is a major obstacle to reducing the morbidity and mortality of hepatitis B. According to the World Health Organization, solving the problem of non-compliance with treatment would represent significant progress. Burkina is a country with high endemicity and the factors associated with non-compliance with treatment remain poorly understood. Objective: This study aims to identify these factors and guide strategies. Methodology: This was a retrospective cohort study of 210 chronic carriers of hepatitis B from 2021-2023 in Burkina. The average scores for compliance with hygiene and dietary measures, compliance with medication intake and follow-up at the 6th; 12th, 18th, 24th month of our study were calculated. We speak of non-compliance with treatment if this average is < 75%. We conducted interviews with patients and performed a documentary review to collect data. The data were processed and analyzed by SAS 9.4® software. Results: The incidence of therapeutic non-compliance was 47.9%, including 60.9% among participants with a monthly income of less than 200,000 FCFA compared to 33.3% among those with an income greater than or equal to 200,000 FCFA. Adjusted for the values present, the factors associated with therapeutic non-compliance are monthly income <200,000 FCFA (p-value = 0.0066), inadequate knowledge of hepatitis B (p-value = 0.0440), age ≥ 50 years (p-value = 0.0191) and male gender (p-value = 0.0256). Conclusion: Hepatitis B treatment non-compliance remains a public health problem in Burkina. Factors associated with non-compliance include low income, inadequate knowledge of hepatitis B, age and gender. Addressing this requires making care more affordable, increasing awareness, diagnostic and management capacities.
| Published in | Science Journal of Public Health (Volume 13, Issue 6) |
| DOI | 10.11648/j.sjph.20251306.11 |
| Page(s) | 321-329 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
Hepatitis B, Chronicity, Treatment Compliance, Burkina Faso
| [1] |
Sciences et Avenir. Hepatite B : definition, symptômes, traitements. Sciences et Avenir. 2014 (cite 1 avr 2023). Disponible sur:
https://www.sciencesetavenir.fr/sante-maladie/hepatite-b-definition-symptomes-traitements_104660 |
| [2] |
WHO. Hepatite B. (cite 1 avr 2023).
https://www.who.int/fr/news-room/fact-sheets/detail/hepatitis-b |
| [3] | Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. The Lancet. 17 oct 2015; 386(10003): 1546-55. |
| [4] | Organisation mondiale de la Sante. Lignes directrices pour la prevention, les soins et le traitement en faveur des personnes atteintes de l’infection à hepatite B chronique. 2018. |
| [5] | Le Burkina Faso et l’objectif mondial d’eliminer le virus de l’hepatite B d’ici 2030 – Kosmos Publishers. (cite 16 janv 2023). |
| [6] | Lingani M, Akita T, Ouoba S, Sanou AM, Sugiyama A, Tarnagda Z, et al. High prevalence of hepatitis B infections in Burkina Faso (1996–2017): a systematic review with meta-analysis of epidemiological studies. BMC Public Health. 25 avr 2018; 18: 551. |
| [7] | Ispas S, So S, Toy M. Barriers to Disease Monitoring and Liver Cancer Surveillance Among Patients with Chronic Hepatitis B in the United States. J Community Health. 1 juin 2019; 44(3): 610-25. |
| [8] | Desbrus-Qochih A, Cathebras P. Obeir ou adherer ? L’observance therapeutique en question. Medecine & Longevite. dec 2012; 4(3-4): 111-22. |
| [9] | Nordling L. Africa’s struggle with hepatitis B. Nature. 30 mars 2022; 603(7903): S60-1. |
| [10] | Some EN, Nana FW, Meda BI, Son M, Maxime D, Kouanda S, et al. Chronic Carriage of Hepatitis B Virus at the University Teaching Hospital Yalgado Ouedraogo: Therapeutic Aspects and Outcome in a Cohort of HBeAg+ Outpatients. Open Journal of Epidemiology. 28 juin 2021; 11(3): 245-55. |
| [11] | Akande KO, Faneye AO, Olusola BA, Otegbayo JA, Arije A, Olaleye DO. Adherence to Medication among Patients with Chronic Hepatitis B Infection Attending a Tertiary Hospital in South Western Nigeria. West Afr J Med. 29 juill 2021; 38(7): 629-33. |
| [12] | Li Y, Chen A, Wang H, Han L, Wang R, Zhang G, et al. Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study. Patient Prefer Adherence. 10 août 2021; 15: 1729-38. |
| [13] | Giang L, Selinger CP, Lee AU. Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires. World J Hepatol. 27 fevr 2012; 4(2): 43-9. |
| [14] | Ozyigitoglu D, Sevgi DY, Tahtasakal CA, Oncul A, Gunduz A, Dokmetas I. Adherence to Treatment with Oral Nucleoside/Nucleotide Analogs in Patients with Chronic Hepatitis B. Sisli Etfal Hastan Tip Bul. 2022; 56(4): 543-51. |
| [15] | Yanogo PK, Sanou EN, Meda N. The Outcome of People Screened For Hepatitis B, in a Community-Based Setting in Ouagadougou, Burkina, 2018-2020. 2022; |
| [16] | Wang L, Chen P, Zheng C. Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B. Infect Drug Resist. 8 nov 2018; 11: 2179-85. |
| [17] | Aljumah AA, Babatin M, Hashim A, Abaalkhail F, Bassil N, Safwat M, et al. Hepatitis B care pathway in Saudi Arabia: Current situation, gaps and actions. Saudi J Gastroenterol. 2019; 25(2): 73-80. |
| [18] | Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. The Lancet Infectious Diseases. 1 dec 2016; 16(12): 1409-22. |
| [19] | Tapper EB, Hao S, Lin M, Mafi JN, McCurdy H, Parikh ND, et al. The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers. Hepatology. janv 2020; 71(1): 225-34. |
| [20] | World Health Organization. Rapport sur la sante dans le monde : 2003 : façonner l’ avenir. Organisation mondiale de la Sante; 2003 (cite 1 avr 2023). Disponible sur: |
| [21] | Ministère de la sante du Burkina Faso. Plan strategique de lutte contre les hepatite virales 2017-2021. 2017. |
| [22] | World Bank Open Data. Taux d’alphabetisation au Burkina. World Bank Open Data. (cite 9 mai 2023). |
| [23] | Wong RJ, Jain MK, Therapondos G, Niu B, Kshirsagar O, Thamer M. Low Rates of Hepatitis B Virus Treatment Among Treatment-Eligible Patients in Safety-Net Health Systems. J Clin Gastroenterol. 1 avr 2022; 56(4): 360-8. |
| [24] | Tütüncü EE, Güner R, Gürbüz Y, Kaya Kalem A, Öztürk B, Hasanoğlu İ, et al. Adherence to Nucleoside/Nucleotide Analogue Treatment in Patients with Chronic Hepatitis B. Balkan Med J. 1 dec 2017; 34(6): 540-5. |
| [25] | Ma GX, Zhu L, Lu W, Tan Y, Truehart J, Johnson C, et al. Examining the Influencing Factors of Chronic Hepatitis B Monitoring Behaviors among Asian Americans: Application of the Information-Motivation-Behavioral Model. International Journal of Environmental Research and Public Health. janv 2022; 19(8): 4642. |
| [26] | Bhimla A, Zhu L, Lu W, Golub S, Enemchukwu C, Handorf E, et al. Factors Associated with Hepatitis B Medication Adherence and Persistence among Underserved Chinese and Vietnamese Americans. J Clin Med. 7 fevr 2022; 11(3): 870. |
| [27] | Sheppard-Law S, Zablotska-Manos I, Kermeen M, Holdaway S, Lee A, George J, et al. Factors associated with non-adherence to HBV antiviral therapy. Antivir Ther. 2018; 23(5): 425-33. |
APA Style
Yanogo, P. K., Sanou, E. N., Traore, I. T., Kabore, J., Balima, C., et al. (2025). Therapeutic Compliance Among Chronic HBV Carriers in Burkina Faso, 2021 - 2023. Science Journal of Public Health, 13(6), 321-329. https://doi.org/10.11648/j.sjph.20251306.11
ACS Style
Yanogo, P. K.; Sanou, E. N.; Traore, I. T.; Kabore, J.; Balima, C., et al. Therapeutic Compliance Among Chronic HBV Carriers in Burkina Faso, 2021 - 2023. Sci. J. Public Health 2025, 13(6), 321-329. doi: 10.11648/j.sjph.20251306.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.sjph.20251306.11,
author = {Pauline Kiswendsida Yanogo and Estelle Nadine Sanou and Isidore Tiandiogo Traore and Jean Kabore and Clarisse Balima and Djibril Barry and Hermann Yoda and Hermann Nikiema and Smaila Ouedraogo and Nicolas Meda},
title = {Therapeutic Compliance Among Chronic HBV Carriers in Burkina Faso, 2021 - 2023},
journal = {Science Journal of Public Health},
volume = {13},
number = {6},
pages = {321-329},
doi = {10.11648/j.sjph.20251306.11},
url = {https://doi.org/10.11648/j.sjph.20251306.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjph.20251306.11},
abstract = {Background: Non-compliance with treatment is a major obstacle to reducing the morbidity and mortality of hepatitis B. According to the World Health Organization, solving the problem of non-compliance with treatment would represent significant progress. Burkina is a country with high endemicity and the factors associated with non-compliance with treatment remain poorly understood. Objective: This study aims to identify these factors and guide strategies. Methodology: This was a retrospective cohort study of 210 chronic carriers of hepatitis B from 2021-2023 in Burkina. The average scores for compliance with hygiene and dietary measures, compliance with medication intake and follow-up at the 6th; 12th, 18th, 24th month of our study were calculated. We speak of non-compliance with treatment if this average is Results: The incidence of therapeutic non-compliance was 47.9%, including 60.9% among participants with a monthly income of less than 200,000 FCFA compared to 33.3% among those with an income greater than or equal to 200,000 FCFA. Adjusted for the values present, the factors associated with therapeutic non-compliance are monthly income Conclusion: Hepatitis B treatment non-compliance remains a public health problem in Burkina. Factors associated with non-compliance include low income, inadequate knowledge of hepatitis B, age and gender. Addressing this requires making care more affordable, increasing awareness, diagnostic and management capacities.},
year = {2025}
}
TY - JOUR T1 - Therapeutic Compliance Among Chronic HBV Carriers in Burkina Faso, 2021 - 2023 AU - Pauline Kiswendsida Yanogo AU - Estelle Nadine Sanou AU - Isidore Tiandiogo Traore AU - Jean Kabore AU - Clarisse Balima AU - Djibril Barry AU - Hermann Yoda AU - Hermann Nikiema AU - Smaila Ouedraogo AU - Nicolas Meda Y1 - 2025/11/28 PY - 2025 N1 - https://doi.org/10.11648/j.sjph.20251306.11 DO - 10.11648/j.sjph.20251306.11 T2 - Science Journal of Public Health JF - Science Journal of Public Health JO - Science Journal of Public Health SP - 321 EP - 329 PB - Science Publishing Group SN - 2328-7950 UR - https://doi.org/10.11648/j.sjph.20251306.11 AB - Background: Non-compliance with treatment is a major obstacle to reducing the morbidity and mortality of hepatitis B. According to the World Health Organization, solving the problem of non-compliance with treatment would represent significant progress. Burkina is a country with high endemicity and the factors associated with non-compliance with treatment remain poorly understood. Objective: This study aims to identify these factors and guide strategies. Methodology: This was a retrospective cohort study of 210 chronic carriers of hepatitis B from 2021-2023 in Burkina. The average scores for compliance with hygiene and dietary measures, compliance with medication intake and follow-up at the 6th; 12th, 18th, 24th month of our study were calculated. We speak of non-compliance with treatment if this average is Results: The incidence of therapeutic non-compliance was 47.9%, including 60.9% among participants with a monthly income of less than 200,000 FCFA compared to 33.3% among those with an income greater than or equal to 200,000 FCFA. Adjusted for the values present, the factors associated with therapeutic non-compliance are monthly income Conclusion: Hepatitis B treatment non-compliance remains a public health problem in Burkina. Factors associated with non-compliance include low income, inadequate knowledge of hepatitis B, age and gender. Addressing this requires making care more affordable, increasing awareness, diagnostic and management capacities. VL - 13 IS - 6 ER -
Burkina Field Epidemiology and Laboratory Training Program, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso; Department of Public Health, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
Burkina Field Epidemiology and Laboratory Training Program, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso; Ministry of Health and Public Hygiene, Ouagadougou, Burkina Faso
Higher Institute of Health Sciences, University Nazi Boni, Bobo-Dioulasso, Burkina Faso
Health Sciences Research Institute, National Center for Scientific and Technological Research, Ouagadougou, Burkina Faso
Burkina Field Epidemiology and Laboratory Training Program, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso; Ministry of Health and Public Hygiene, Ouagadougou, Burkina Faso
Burkina Field Epidemiology and Laboratory Training Program, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
Burkina Field Epidemiology and Laboratory Training Program, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
Burkina Field Epidemiology and Laboratory Training Program, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
Department of Public Health, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
Burkina Field Epidemiology and Laboratory Training Program, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso; Department of Public Health, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
Information